People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Other Technology, Manufacturing, Biotechnology, Other Health Care, Mining & Resources, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Songkick.com, Inc. | — | Other Technology | Series B | $18.6M | $508.9M | 2011 |
| Voltaix, Inc. | — | Manufacturing | Series A | $15.0M | $149.8M | 2012 |
| Remix Therapeutics, Inc. | — | Biotechnology | Series A | $13.7M | $93.0M | 2023 |
| Voyager Biomedical, Inc. | — | Other Health Care | Series A | $6.8M | $21.6M | 2019 |
| Cabral Gold Inc. | — | Mining & Resources | Seed | $6.4M | $603K | 2020 |
| SkinIO, LLC | — | Other Health Care | Seed | $6.1M | $12.6M | 2015 |
| Vortex Control Technologies LLC | — | Other Technology | Seed | $3.3M | $28.4M | 2014 |
| Steelmax Tools LLC | — | Other | Seed | $2.0M | $36.9M | 2010 |
| Global New Media, Inc. | — | Other Technology | Pre-Seed | $451K | $19.1M | 2009 |
Peter Smith at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter Smith on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mark Smith | 1 | 28 |
| Robert Smith | 1 | 17 |
| Kevin Bitterman | 1 | 15 |
| Ashok Gowda | 1 | 12 |
| Matthew Jones | 1 | 9 |
| Alan Carter | 1 | 8 |
| Linda Spain | 1 | 6 |
| John A Moore | 1 | 6 |
| Dennis Moore | 1 | 5 |
| Saul Klein | 1 | 5 |
| Derrick Weyrauch | 1 | 4 |
| Jeff Goater | 1 | 4 |
| Brett Smith | 1 | 4 |
| Frank O'Donnell | 1 | 3 |
| Paul Hansed | 1 | 3 |
| Samantha Shorter | 1 | 3 |
| Matthew Patterson | 1 | 3 |
| Michael Rome | 1 | 3 |
| Adam Ray | 1 | 3 |
| Derek Roberts | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.